Skip to main content

Moderna Inc(MRNA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low48.72
Day High51.36
Open:50.63
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Which Is the Better iShares ETF for Small-Cap Value Investing, ISCV or IWN?
Tipranks
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Moderna (MRNA)
Motley Fool
3 Healthcare Stocks With the Most Durable Competitive Moats
Tipranks
Bernstein Keeps Their Hold Rating on Moderna (MRNA)
Motley Fool
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth
Tipranks
Bank of America Securities Reaffirms Their Sell Rating on Moderna (MRNA)
StockStory
3 Unpopular Stocks We Approach with Caution
MRNA
Motley Fool
A $2 Trillion IPO and the Space Economy
Tipranks
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP), Armata Pharmaceuticals (ARMP) and Moderna (MRNA)
Motley Fool
Meet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year. Are They Still a Buy?
StockStory
3 Mid-Cap Stocks We’re Skeptical Of
IP
Motley Fool
Looks Like M&A Week in 3 Different Sectors
Motley Fool
You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500.
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT) and Moderna (MRNA)
Tipranks
Moderna Advances Phase 3 H5 Bird Flu Shot, Expanding Its Pandemic Vaccine Pipeline
StockStory
2 S&P 500 Stocks with Exciting Potential and 1 We Ignore
AMD
StockStory
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
HIMS
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Palisade Bio (PALI) and Moderna (MRNA)
StockStory
Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna Shares Plummet, What You Need To Know
AZTA
Motley Fool
2 Healthcare Stocks That Could Soar Over the Next 5 Years
Motley Fool
Moderna Stock is Soaring. Is It Too Late to Buy?
Tipranks
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Xencor (XNCR)
StockStory
2 Mooning Stocks to Target This Week and 1 We Avoid
EXPE
StockStory
Therapeutics Stocks Q4 Teardown: Moderna (NASDAQ:MRNA) Vs The Rest
MRNA
Motley Fool
Pfizer vs Moderna: Which Pharma Stock Has More Upside?
Motley Fool
ISCV vs. VBR: Which Small Cap Value Approach is Right for Investors?
Motley Fool
Looking for Small-Cap Value? Consider These 2 ETFs
Zacks Investment Research
GSK's RSV Vaccine Arexvy Wins FDA Nod for High-Risk Younger Adults
GSK's RSV Vaccine Arexvy Wins FDA Nod for High-Risk Younger Adults
Zacks Investment Research
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave
MarketBeat
The S&P 500's 3 Best-Performing Stocks so far in 2026
MarketBeat.com
Tipranks
Moderna’s Multi-Pathogen mRNA Study Reaches Completion, Supporting a Broader Vaccine Platform
StockStory
3 Healthcare Stocks We’re Skeptical Of
MRNA

Profile

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.